On the basis of several observations the postulate has been created that in the early stages of breast cancer development, the mammary epithelial stem cell population is still sensitive to growth inhibition by TGF-β (and, thus, sensitive to tamoxifen if there is an ER+ subpopulation). This evidence concerns the gene TGFB1 and breast carcinoma.